Loading
A phase 1/2 trial of Tulmimetostat DL1 QD in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) is a phase 1/2 interventional study registered as NCT07206056 by Novartis Pharmaceuticals, with 188 participants planned, started 2025-10-15 and due to reach its primary completion in 2029-11-09. Interventions recorded: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD and JSB462 Dose 1 QD.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced Accelerator Applications (Novartis), Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Advanced Accelerator Applications (Novartis), Novartis and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer, Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/